Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28045970.
- Also identified by DOI 10.1371/journal.pmed.1002190 and PMC identifier 5207392.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
Medical subject headings
- Drug Approval
- Health Policy
- Orphan Drug Production